Hypofractionated Postmastectomy Radiotherapy (HF-PMRT): What did We Learn from COVID-19 Era?
Objectives: In breast cancer (BC) patients receiving mastectomy, postmastectomy radiotherapy (PMRT) improves long-term outcomes by decreasing local failure and cancer mortality. However, the optimal PMRT schedule is still under investigation. The present review aims to discuss the evidence regarding...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2023-02-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/50/2/10.31083/j.ceog5002041 |
| _version_ | 1797893217565278208 |
|---|---|
| author | Viola Salvestrini Carlotta Becherini Luca Visani Isacco Desideri Ilaria Morelli Erika Scoccimarro Cecilia Cerbai Ilaria Bonaparte Niccolo Bertini Beatrice Bettazzi Vieri Scotti Marco Bernini Lorenzo Orzalesi Jacopo Nori Simonetta Bianchi Giulio Francolini Icro Meattini Lorenzo Livi |
| author_facet | Viola Salvestrini Carlotta Becherini Luca Visani Isacco Desideri Ilaria Morelli Erika Scoccimarro Cecilia Cerbai Ilaria Bonaparte Niccolo Bertini Beatrice Bettazzi Vieri Scotti Marco Bernini Lorenzo Orzalesi Jacopo Nori Simonetta Bianchi Giulio Francolini Icro Meattini Lorenzo Livi |
| author_sort | Viola Salvestrini |
| collection | DOAJ |
| description | Objectives: In breast cancer (BC) patients receiving mastectomy, postmastectomy radiotherapy (PMRT) improves long-term outcomes by decreasing local failure and cancer mortality. However, the optimal PMRT schedule is still under investigation. The present review aims to discuss the evidence regarding hypofractionated (HF) PMRT in BC patients in order to identify the optimal treatment approach. Additional purpose is to highlight what we have learned from COVID-19 era regarding HF schedules for PMRT in BC patients. Mechanism: Between February and November 2021, literature and database research were conducted. Key references were detected from a PubMed query. Range of publication date was between 2000 and 2021. Selection criteria included English language publications in humans. Hand searching included meeting proceedings of the European Society for Radiotherapy and Oncology (ESTRO), European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and American Society for Radiation Oncology (ASTRO). The website clinicaltrials.gov was also searched. Randomized controlled trials evaluating HF-PMRT were included. Findings in brief: Our research returned 87 published papers. Fourteen trials were included in our final analysis. The comparisons of several different schedules of HF-PMRT with conventional fractionated PMRT provided similar results in terms of locoregional disease control without increasing toxicity. Particularly, an acute skin toxicity incidence grade 2 or higher ranged between 10 and 25% among the studies we analyzed. Conclusions: The present paper suggests that safety and efficacy of HF-PMRT is comparable with conventional schedules and standard practice guidelines are already available. COVID-19 pandemic has emphasised the need for increasingly tailored treatment protocols. Modern HF regimens should continue to be the standard of treatment in BC patients who receive PMRT also in the post-COVID-19 era. |
| first_indexed | 2024-04-10T06:49:21Z |
| format | Article |
| id | doaj.art-5032b519725644fba1b0f7451165f7d5 |
| institution | Directory Open Access Journal |
| issn | 0390-6663 |
| language | English |
| last_indexed | 2024-04-10T06:49:21Z |
| publishDate | 2023-02-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj.art-5032b519725644fba1b0f7451165f7d52023-02-28T08:29:05ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632023-02-015024110.31083/j.ceog5002041S0390-6663(22)01976-5Hypofractionated Postmastectomy Radiotherapy (HF-PMRT): What did We Learn from COVID-19 Era?Viola Salvestrini0Carlotta Becherini1Luca Visani2Isacco Desideri3Ilaria Morelli4Erika Scoccimarro5Cecilia Cerbai6Ilaria Bonaparte7Niccolo Bertini8Beatrice Bettazzi9Vieri Scotti10Marco Bernini11Lorenzo Orzalesi12Jacopo Nori13Simonetta Bianchi14Giulio Francolini15Icro Meattini16Lorenzo Livi17Radiation Oncology Unit, Cyberknife Centre, IFCA Istituto Fiorentino di Cura e Assistenza, 50139 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Cyberknife Centre, IFCA Istituto Fiorentino di Cura e Assistenza, 50139 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyBreast Surgery Unit, Florence University Hospital, 50134 Florence, ItalyBreast Surgery Unit, Florence University Hospital, 50134 Florence, ItalySenology Diagnostic Unit, Florence University Hospital, 50134 Florence, ItalyPathology Unit, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyRadiation Oncology Unit, Department of Oncology, Florence University Hospital, 50134 Florence, ItalyObjectives: In breast cancer (BC) patients receiving mastectomy, postmastectomy radiotherapy (PMRT) improves long-term outcomes by decreasing local failure and cancer mortality. However, the optimal PMRT schedule is still under investigation. The present review aims to discuss the evidence regarding hypofractionated (HF) PMRT in BC patients in order to identify the optimal treatment approach. Additional purpose is to highlight what we have learned from COVID-19 era regarding HF schedules for PMRT in BC patients. Mechanism: Between February and November 2021, literature and database research were conducted. Key references were detected from a PubMed query. Range of publication date was between 2000 and 2021. Selection criteria included English language publications in humans. Hand searching included meeting proceedings of the European Society for Radiotherapy and Oncology (ESTRO), European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and American Society for Radiation Oncology (ASTRO). The website clinicaltrials.gov was also searched. Randomized controlled trials evaluating HF-PMRT were included. Findings in brief: Our research returned 87 published papers. Fourteen trials were included in our final analysis. The comparisons of several different schedules of HF-PMRT with conventional fractionated PMRT provided similar results in terms of locoregional disease control without increasing toxicity. Particularly, an acute skin toxicity incidence grade 2 or higher ranged between 10 and 25% among the studies we analyzed. Conclusions: The present paper suggests that safety and efficacy of HF-PMRT is comparable with conventional schedules and standard practice guidelines are already available. COVID-19 pandemic has emphasised the need for increasingly tailored treatment protocols. Modern HF regimens should continue to be the standard of treatment in BC patients who receive PMRT also in the post-COVID-19 era.https://www.imrpress.com/journal/CEOG/50/2/10.31083/j.ceog5002041breast cancerhypofractionated post-mastectomy radiotherapyconventional fractionated pmrtcovid-19 pandemics |
| spellingShingle | Viola Salvestrini Carlotta Becherini Luca Visani Isacco Desideri Ilaria Morelli Erika Scoccimarro Cecilia Cerbai Ilaria Bonaparte Niccolo Bertini Beatrice Bettazzi Vieri Scotti Marco Bernini Lorenzo Orzalesi Jacopo Nori Simonetta Bianchi Giulio Francolini Icro Meattini Lorenzo Livi Hypofractionated Postmastectomy Radiotherapy (HF-PMRT): What did We Learn from COVID-19 Era? Clinical and Experimental Obstetrics & Gynecology breast cancer hypofractionated post-mastectomy radiotherapy conventional fractionated pmrt covid-19 pandemics |
| title | Hypofractionated Postmastectomy Radiotherapy (HF-PMRT): What did We Learn from COVID-19 Era? |
| title_full | Hypofractionated Postmastectomy Radiotherapy (HF-PMRT): What did We Learn from COVID-19 Era? |
| title_fullStr | Hypofractionated Postmastectomy Radiotherapy (HF-PMRT): What did We Learn from COVID-19 Era? |
| title_full_unstemmed | Hypofractionated Postmastectomy Radiotherapy (HF-PMRT): What did We Learn from COVID-19 Era? |
| title_short | Hypofractionated Postmastectomy Radiotherapy (HF-PMRT): What did We Learn from COVID-19 Era? |
| title_sort | hypofractionated postmastectomy radiotherapy hf pmrt what did we learn from covid 19 era |
| topic | breast cancer hypofractionated post-mastectomy radiotherapy conventional fractionated pmrt covid-19 pandemics |
| url | https://www.imrpress.com/journal/CEOG/50/2/10.31083/j.ceog5002041 |
| work_keys_str_mv | AT violasalvestrini hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT carlottabecherini hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT lucavisani hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT isaccodesideri hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT ilariamorelli hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT erikascoccimarro hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT ceciliacerbai hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT ilariabonaparte hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT niccolobertini hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT beatricebettazzi hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT vieriscotti hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT marcobernini hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT lorenzoorzalesi hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT jacoponori hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT simonettabianchi hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT giuliofrancolini hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT icromeattini hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era AT lorenzolivi hypofractionatedpostmastectomyradiotherapyhfpmrtwhatdidwelearnfromcovid19era |